Business Description
Founded in 2006 and based in Stafford, Texas, Greenwich LifeSciences is working to bring new treatment options to breast cancer patients. The company's primary focus is GP2, an immune-based therapy currently in late-stage clinical testing aimed at stopping breast cancer from returning after surgery. A second program, GLSI-100, is also in Phase III trials and targets a specific group of patients whose tumors carry high levels of the HER2 protein.
